Wyeth To Announce Promising New Data For Enbrel(R) In Rheumatology
Wyeth Pharmaceuticals revealed highlights from data to be presented on its biologic therapy Enbrel® (etanercept), at the European League Against Rheumatism (EULAR) Annual Meeting in Paris, 11-14 June 2008. Highlights of the data to be presented include: - New 1-year radiographic remission results from the COMET trial (COmbination of Methotrexate and ETanercept in early active rheumatoid arthritis), along with clinical and functional remission results.
More: continued here
Filed under: Arthritis on June 11th, 2008